/biz/ - Business & Finance

>>55476408
>If you look at the reasons for patient discontinuations all are likely unrelated to the drug

Huh? Athralgia was not related to the drug? It 100% is. Athralgia is absolutely an effect of drugs GH and IGF-1 suppression.

>What specific pharmacokinetics do you find to be concerning that would likely make this drug not continue through P3?
Okay so with pk issues, the slide that CRNX showed (pic related), it does not make sense to me what dosing up to 60 is supposed to do when 20/30 is pretty much flatlining. They have a new formulation but the exposure isn’t really that much better, they have lower cmax/AUC at 20/30mg comparatively which then show a greater dose response at higher doses, but the AUC is in line with the old formulation.

Another skeleton in CRNX's closet is that they never showed us the results based on the Phase 3 endpoint responder analysis which is IGF-1 <1.0 ULN…they only showed mean change of IGF-1. Which is a really bad measure esp when we know this drug suppressed IGF-1 substantially in some patients.

Testing if this post goes through. It's a pic about CRNX's drug pharmacokinetic issues. It's unsafe after a certain dose